Edison Investment provided color on Ziopharm Oncology ZIOP. In a research report published today, Edison stressed its optimism about the company's long term outlook.
In the report, Edison states, “Ziopharm has a catalyst on the horizon – the read out from the Phase III trial of
palifosphamide in soft tissue sarcoma, due mid-2012. With three drugs in clinical
trials, an EV of $272m suggests investors are not attributing much value to the high
potential synthetic biology platform.”
On Tuesday, Ziopharm lost 1.17% of its value to finish the day at $5.93.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in